

ГАСТРОЭНТЕРОЛОГИИ

И

НУТРИЦИОЛОГИИ



(/IPP)

:

⋮

I _____ ⋮

Ø (1978 ., 1989 . - .) -

Ø (,).

Ø (,).

II _____ ⋮

Ø (,)

III _____ ⋮

Ø () - S-

-

2001 .

?


per os

(-)


(. . - 1000 ,)

()

+ / + -




PPI



Adapted from Sachs G, et al. *Annu Rev Pharmacol Toxicol*. 1995;35:277-305.

PPI



Adapted from Sachs G, et al. *Annu Rev Pharmacol Toxicol*. 1995;35:277-305.

in vivo

'
>> (UC),

· ·
:


<<

>> ,


<<

>> ,

AUC



(in vitro)



7-8

in vivo:

>4

16 (

):

- 40 / - 50%
- 30 / - 5%,
- 40 / - 10%,
- 20 / - 25%.



Ø

Ø

Ø

Ø

Ø

Ø


Ø

).)

?

?

Helicobacter pylori





/

2⁺

/



/




/

.



-

Meta-analysis



* $P < .001$ vs H2RAs.

Chiba N et al. *Gastroenterology*. 1997;112:1798-1810.

Helicobacter pylori

-
-
-
- H in vitro () > (10) > (100) > (4) : (16) > 2⁻ in vivo
- (- 2% - 5%).
- - Hp :
- ((+) H ,) .
-



•

2⁻

,

:

- : +11% - 4 (- , n=3504),

- : +10% - 4 (-).

•

,

2⁻

,

•

40

/

-

,

,

,

- 20

/c .

•

= = =

•

,

(

).



•

2⁻

,

:

- : + 11% - 4 (- , n = 347),
- : + 33% - 4 (- , n = 1500).

•

,

- 10% - 15%.

2⁻

•

:

8

40 /

/ -

> 1 : 83%

20
75%

•

= = = -


.

•

,

(

).



/

•

/

2⁻

/

(-

1970 - 1999 .).






•

/

:

•



CYP2C19 CYP3A4 II () - CYP450				
	++++	++	-	-
	+++	+++	-	-
	++++	++	+++++	-
	+	+	-	++++
	+/-	+/-	-	++++

CYP2C19

		-	-
	75%	22%	3%
	66%	31%	3%
	—	—	15%
	—	—	30%

- **10 (1990-2000)**

10 000 000

5669 10 008

2530, - 3556, - 808.


• _____

— / / / :

: 0,5% - 2% -

– : 2% –

10% - 18% -



()

_____ :

• :

/ / /

/

/

/ / /

/

/

/ /

. 12,

/ / /

/

/

;


• :

/ / /


/

/

.



()



⋮

• FDA:

•
•

•

/

-

«

»

-2000 (

3).

•

/

/

/

/

/

2⁺

•

in vivo:

> = = = .

: = = = > 2⁻

CYP2C19 (. .

) - .

:

4%

- 2% -

